Travere CMO gets options, sells shares for taxes

Travere Therapeutics’ chief medical officer, Jula Inrig, reported equity grants and a tax-related share sale.

Rhea-AI Filing Summary

Travere Therapeutics’ chief medical officer, Jula Inrig, reported equity grants and a tax-related share sale. On 01/31/2026, she acquired 28,130 shares of common stock at $0 through restricted stock unit settlement, bringing her holdings to 114,441 shares before a later sale.

That same day she received an employee stock option for 75,000 shares of common stock at an exercise price of $33.095, expiring on 01/31/2036, with vesting over four years. On 02/03/2026, she sold 6,956 shares of common stock at $32.12 per share to cover tax withholding from the vested units, a mandated “sell to cover” transaction, not a discretionary trade. After the sale, she directly owned 107,485 common shares and 75,000 stock options.

Insider Trade Summary

Net Seller: 6,956 shares

Net Sell 3 txns

Insider Inrig Jula

Role CHIEF MEDICAL OFFICER

Sold 6,956 shs ($223K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,956	$32.12	$223K
Grant/Award	Employee stock option (right to buy)	75,000	$0.00	$0.00
Grant/Award	Common Stock	28,130	$0.00	$0.00

Holdings After Transaction: Employee stock option (right to buy) — 75,000 contracts (Direct); Common Stock — 107,485 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
2. F2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
3. F3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Travere Therapeutics (TVTX) report for Jula Inrig?

Travere Therapeutics reported that CMO Jula Inrig received 28,130 shares from vested restricted stock units and an option for 75,000 shares. She also sold 6,956 shares to cover tax withholding on the vesting, leaving 107,485 shares directly owned.

How many Travere Therapeutics (TVTX) shares does Jula Inrig own after these Form 4 transactions?

After the reported transactions, Jula Inrig directly owns 107,485 shares of Travere common stock. She also holds an employee stock option covering 75,000 additional shares, giving her a combination of current ownership and future exercisable rights.

Why did Jula Inrig sell 6,956 Travere Therapeutics (TVTX) shares?

She sold 6,956 shares solely to cover tax withholding triggered by the settlement of vested restricted stock units. The company’s equity plan mandates a “sell to cover” transaction through a designated broker, so this sale was not a discretionary trade.

What are the key terms of Jula Inrig’s new Travere (TVTX) stock option grant?

The new employee stock option covers 75,000 shares of Travere common stock at an exercise price of $33.095. One-fourth vests after one year from grant, with the remaining shares vesting in 36 equal monthly installments through the option’s 2036 expiration.

How were the 28,130 Travere Therapeutics (TVTX) shares acquired by Jula Inrig?

The 28,130 shares were received through the settlement of restricted stock units, each unit representing one share of common stock. These vested units converted at no cash cost, increasing her direct share ownership before the subsequent tax-related sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Inrig Jula

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, SUITE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A(1)		28,130	A	$0	114,441	D
Common Stock	02/03/2026		S(2)		6,956	D	$32.12	107,485	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$33.095	01/31/2026		A		75,000		(3)	01/31/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

2. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.